Feng Shi, Chen Ruihan, Huang Haitao, Ong Meiching, Jiang Jingyu, Cui Jinlong, Ling Qi
Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Ann Surg Oncol. 2025 Jun 7. doi: 10.1245/s10434-025-17540-1.
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with poor prognosis. Exploring novel serum biomarkers and the underlying mechanism is crucial for the early diagnosis and precise therapy of PDAC.
Exosomal microRNAs (exo-miRNAs) isolated from serum samples of 92 PDAC patients and 44 healthy subjects were detected by small RNA sequencing, and their diagnostic performance and prognostic value were evaluated. In vitro experiments and orthotopic PDAC mouse model were conducted to investigate the effect of miR-519a/522-5p. Integrated transcriptomics and metabolomics were used to explore the underlying mechanism of miR-519a/522-5p dysregulation.
Compared with the healthy control, all three PDAC subgroups (stage I-III) displayed a specific deregulated serum exo-miRNA profile. A panel of 3 serum exo-miRNAs (let-7g-3p, miR-490-5p, and miR-519a/522-5p) was established as novel diagnostic biomarkers for PDAC, which exhibited high sensitivity and specificity in clinical cohort. MiR-519a/522-5p was found to be an independent prognostic factor for PDAC and associated with tumor features particularly invasion/metastasis. In vitro and in vivo experiments confirmed that miR-519a/522-5p promoted invasiveness/metastasis of PDAC cells. Moreover, miR-519a/522-5p could be effectively delivered via exosomes and increased the invasiveness of recipient cancer cells. Multi-omics analysis showed a comprehensive miR-519a/522-5p-regulated molecular network, in which glycolysis played a central role. We further validated that miR-519a/522-5p enhanced glycolysis by targeting SESN2.
Serum exo-miRNAs could be promising candidates for precise diagnosis and treatment of PDAC. Exo-miR-519a/522-5p promotes PDAC cellular invasiveness by enhancing Warburg effect through intercellular transportation.
胰腺导管腺癌(PDAC)是一种侵袭性很强的恶性肿瘤,预后较差。探索新型血清生物标志物及其潜在机制对于PDAC的早期诊断和精准治疗至关重要。
通过小RNA测序检测从92例PDAC患者和44例健康受试者的血清样本中分离出的外泌体微小RNA(exo-miRNA),并评估其诊断性能和预后价值。进行体外实验和原位PDAC小鼠模型以研究miR-519a/522-5p的作用。采用综合转录组学和代谢组学来探索miR-519a/522-5p失调的潜在机制。
与健康对照相比,所有三个PDAC亚组(I-III期)均表现出特定的血清外泌体miRNA谱失调。一组3种血清外泌体miRNA(let-7g-3p、miR-490-5p和miR-519a/522-5p)被确立为PDAC的新型诊断生物标志物,在临床队列中表现出高敏感性和特异性。发现miR-519a/522-5p是PDAC的独立预后因素,且与肿瘤特征尤其是侵袭/转移相关。体外和体内实验证实miR-519a/522-5p促进了PDAC细胞的侵袭性/转移性。此外,miR-519a/522-5p可通过外泌体有效传递并增加受体癌细胞的侵袭性。多组学分析显示了一个全面的miR-519a/522-5p调控分子网络,其中糖酵解起核心作用。我们进一步验证了miR-519a/522-5p通过靶向SESN2增强糖酵解。
血清外泌体miRNA可能是PDAC精准诊断和治疗的有前景的候选物。外泌体miR-519a/522-5p通过细胞间运输增强瓦伯格效应,从而促进PDAC细胞的侵袭性。